StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by atomicnumber31on Nov 15, 2019 11:37am

128 Views

Post# 30356791

RE:RE:RE:RE:RE:RE:RE:So according to Tripp

johnny007 wrote: I agree with the negativity here of course.
The next cash raise will happen very soon now (this quarter almost done and they keep spending) - so the raise will not be at the lofty 11.5c I guess, might be toxic again. That would be a big red flat and starting at just 4c .. well, we talk about month long slow decline as they sell below VWAP.

Then the OS will have been multiplied .. and what not.
One day, there will be probably the next hype running - but from which price level?

I lean back and will slowly watch this further, not being surprised of anything. Even a complete retracement to like 2c is possible if they cannot get appropriate funding.

Maybe Rory should say something cough cough.

Good luck.

Every dog has its day....

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale